Alisol A is a bioactive triterpenoid isolated from the Rhizoma Alismatis. Alisol A inhibited the proliferation, migration, and invasion of NPC (nasopharyngeal carcinoma) cells by inhibiting the Hippo signaling pathway. In addition, Alisol A promoted the phosphorylation of YAP and suppressed the expression of YAP in NPC cells[3]. Alisol A remarkably decreased lipid levels, alleviated glucose metabolism disorders and insulin resistance in high-fat-diet-induced obese mice. Alisol A reduced hepatic steatosis and improved liver function in the obese mice model[4]. Alisol A can effectively inhibit the formation of arterial plaques and blocked the progression of AS in ApoE-/- mice fed with high-fat diet and significantly reduced the expression of inflammatory cytokins in aorta, including ICAM-1, IL-6, and MMP-9. Alisol A activated the AMPK/SIRT1 signaling pathway and NF-κB inhibitor IκBα in HepG2 cells[5].
Alisol A/泽泻醇A 细胞实验
Cell Line
Concentration
Treated Time
Description
References
Human aortic endothelial cells (HAECs)
20 μM
48 h
To evaluate the effect of Alisol A on NO secretion, results showed that Alisol A promoted NO secretion.
Front Pharmacol. 2024 Oct 25;15:1493948
Human aortic endothelial cells (HAECs)
10 μM, 20 μM
6 h
To evaluate the effect of Alisol A on angiogenesis, results showed that Alisol A significantly inhibited the angiogenesis ability of vascular endothelial cells.
Front Pharmacol. 2024 Oct 25;15:1493948
Human aortic endothelial cells (HAECs)
5 μM, 10 μM, 20 μM
8 h
To evaluate the effect of Alisol A on cell migration, results showed that Alisol A significantly inhibited the migration of vascular endothelial cells.
Front Pharmacol. 2024 Oct 25;15:1493948
Human aortic endothelial cells (HAECs)
40 μM
24 h
To evaluate the effect of Alisol A on cell proliferation, results showed that Alisol A significantly inhibited the proliferation of vascular endothelial cells.
Front Pharmacol. 2024 Oct 25;15:1493948
HepG2 cells
0, 1, 5, 10, 20, 30, 40, 60, 80, 100 μM
24 and 48 h
To evaluate the effect of Alisol A on HepG2 cell viability. Results showed that 0-30 mM Alisol A treatment for 24-48 hours did not significantly affect HepG2 cell viability.
Front Pharmacol. 2020 Nov 2;11:580073
HepG2 cells
1, 5, 10, 20 μM
24 h
To evaluate the effect of Alisol A on lipid accumulation in HepG2 cells. Results showed that Alisol A dose-dependently inhibited FFA-induced lipid accumulation, with the 20 mM group being significantly lower than the model group.
Front Pharmacol. 2020 Nov 2;11:580073
chondrocytes
20 μM
24 h
To evaluate the protective effect of Alisol A on IL-1β-induced inflammation and matrix degradation in chondrocytes, results showed that Alisol A could promote PPARγ expression and inhibit the downregulation of collagen II and the production of MMP-13.
Front Pharmacol. 2022 Nov 23;13:993498
HepG2 cells
1, 2, 5 μM
To investigate the effect of Alisol A on the AMPK/ACC/SREBP-1c pathway. Results showed that Alisol A could concentration-dependently restore the levels of p-AMPK and p-ACC in FFA-treated HepG2 cells.
J Cell Mol Med. 2019 Aug;23(8):5108-5118
HK1 cells
10, 20, and 40 μM
24, 48, and 72 h
Alisol A significantly inhibited the growth of HK1 cells in a time- and concentration-dependent manner.
Yonsei Med J. 2021 Oct;62(10):895-902
C666-1 cells
10, 20, and 40 μM
24, 48, and 72 h
Alisol A significantly inhibited the growth of C666-1 cells in a time- and concentration-dependent manner.
Yonsei Med J. 2021 Oct;62(10):895-902
HT-29 cells
5, 10, 20, 40, 80, 160 µM
24 h
Alisol A inhibited HT-29 cell proliferation in a dose-dependent manner.
Oncol Lett. 2022 Jun 7;24(2):249
HCT-116 cells
5, 10, 20, 40, 80, 160 µM
24 h
Alisol A inhibited HCT-116 cell proliferation in a dose-dependent manner.
Oncol Lett. 2022 Jun 7;24(2):249
BV2 cells
10 μM
24 h
To evaluate the inhibitory effect of Alisol A on PA-induced BV2 cell activation. Results showed that Alisol A significantly inhibited PA-induced M1 polarization of BV2 cells and reduced the expression of inflammatory factors TNF-α, IL-1β, IL-6, iNOS, and CD16/32.
Mol Neurobiol. 2024 Feb;61(2):753-771
Alisol A/泽泻醇A 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Zebrafish
Diabetic retinopathy model
Immersion administration
3 μM, 10 μM, 30 μM
Culture medium replaced every 24 hours for 7 consecutive days
Alisol A significantly inhibited fundus angiogenesis and retinal edema, and acted by inhibiting the PI3K/Akt/eNOS signaling pathway.
Drug Des Devel Ther. 2024 Jul 30;18:3361-3382
ApoE-/- mice
High-fat diet-induced atherosclerosis model
Oral
150 mg/kg
Once daily for 16 weeks
To evaluate the effect of Alisol A on atherosclerotic plaques, results showed that Alisol A significantly reduced the aortic plaque area.
Front Pharmacol. 2024 Oct 25;15:1493948
C57BL/6 mice
High-fat-diet-induced obese mouse model
Intraperitoneal injection
100 mg/kg
Once daily for 4 weeks
To evaluate the effects of Alisol A on body weight, lipid metabolism, glucose metabolism, and hepatic steatosis in high-fat-diet-induced obese mice. Results showed that Alisol A significantly reduced body weight, abdominal fat weight, improved lipid and glucose metabolism, and reduced hepatic steatosis.
J Cell Mol Med. 2019 Aug;23(8):5108-5118
C57BL6/J mice
High-fat diet-induced brain aging model
Gavage
50 mg/kg
Once daily for 12 weeks
To evaluate the neuroprotective effects of Alisol A on high-fat diet-induced brain aging. Results showed that Alisol A improved cognitive function, reduced neuroinflammation, increased hippocampal neuron numbers, and protected blood-brain barrier integrity.
Mol Neurobiol. 2024 Feb;61(2):753-771
C57BL/6J mice
Cerebral ischemia model
Gavage
30 mg/kg
Once daily for 7 consecutive days
Alisol A exerts neurovascular protection in the hippocampus of CI mice by activating the AKT/GSK3β pathway.
搜索
